Biomarin Pharmaceutical IncChange company Symbol lookupSelect an option...BMRN Biomarin Pharmaceutical IncADXRF Adx Energy LtdCPB Campbell Soup CoBLTS Bright Lights Acquisition CorpMMM 3M CoSTRR Star Equity Holdings IncBMY Bristol-Myers Squibb CoBCTX Briacell Therapeutics CorpENV Envestnet IncCDR-B Cedar Realty Trust IncGo
Change company Symbol lookup
Select an option...
BMRN Biomarin Pharmaceutical Inc
ADXRF Adx Energy Ltd
CPB Campbell Soup Co
BLTS Bright Lights Acquisition Corp
MMM 3M Co
STRR Star Equity Holdings Inc
BMY Bristol-Myers Squibb Co
BCTX Briacell Therapeutics Corp
ENV Envestnet Inc
CDR-B Cedar Realty Trust Inc
Health Care : Biotechnology | Mid Cap Growth
Company profileBioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
|
|
|
|
| |
| Annual Earnings Missed Consensus (Year ending 12/2021) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Annual Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced February 23, 2022 | -$0.35 | Annual Consensus of 17 analysts | -$0.27 | Difference from consensus | -21.71% | 2022 Earnings will announce | (Unconfirmed) July 27, 2022 |
Annual Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
BMRN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.